Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

McDermott Will & Emery joins HPW as Title Sponsor

4 Mar

By Gregory Mannix, Vice President International Business Development, LSN

Life Science Nation (LSN) is joining forces with McDermott Will & Emery to bring insight and education to the community of investors, service providers, and early-stage companies at Healthtech Partnering Week (HPW). HPW features McDermott Will & Emery at Redefining Early Stage Investments (RESI), March 15-17 and 4D Meets AI, March 18-19.

At RESI, the MWE team will showcase their insights and expertise working with successful organizations to achieve their goals for over eighty-five years. The firm will host a workshop on the all-important topic of Negotiating Term Sheets. This interactive workshop will provide wisdom to early stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

Partner Brian Malkin, JD will also moderate 4D Meets AI’s Drugs panel discussing the importance of early-stage partnerships in therapeutics and highlighting investors speaking with their portfolio companies on the secrets to their successful partnerships

Sign up for HPW to get to know the MWE team and learn how their team is partnering with entrepreneurs to move their companies forward. Attendees for both RESI and 4D Meets AI can save on bundle pricing – Click here to learn more!

Get involved with sponsorship at Healthtech Partnering Week

Healthtech Partnering Week: Meet the Panelists!

25 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

Healthtech Partnering Week (HPW) launches in a few weeks and we want to highlight our esteemed panel faculty coming together to share the latest insights in early-stage life science and healthcare. Each panel is structured to tackle a variety of concerns relevant to fundraising executives that are timely and relevant to each major sector, and even specific indications.

Click the panelist photo below to learn more about their panel participation and to sign up for HPW!


Sascha Berger
TVM Capital Life Science
Jean Anne Booth
UnaliWear Inc.
Nat Brinn
VC23
Ivan Burkov
INKEF Capital

Barbara Clarke
The Impact Sea
Evan Cohen
Healthbox
Michele Colucci
DigitalDx Ventures
Marina Cortes
Hike Ventures LLC

Terence Craig
The Impact Seat
Ruchi Dana
DANA Group of Companies
Anne DeGheest
HealthTech Capital
Bettina Ernst
BERNINA BioInvest

Howard Fillit
Alzheimers Drug Discovery Foundation
Mary Furlong
Mary Furlong & Associates
Robert Garber
7wire Ventures
Amit Garg
Tau Ventures

Scott Gazelle
GreyBird Ventures
Tom Gibbs
Debiopharm Innovation Fund
Sam Goldberger
Ambit Health Ventures
Mark Gray
Constant Companion

Chris Haskell
Bayer
Katherine Hill Ritchie
Nottingham Spirk Family Office
Richard Hughen
Linshom
Alicia Irurzun-Lafitte
UCB Ventures

Stephen Johnston
Aging2.0
Kobus Jooste
Syllable
Arnd Kaltofen
VI Partners
Justin Kelly
AXA Venture Partners

Chris Kent
ODS Medical Inc.
Oliver Keown
Intuitive Surgical
Lily Kim
OS Fund
Kristin King
Boston Harbor Angels

Richard Kivel
GrayBella Capital
Daniella Kranjac
Dynamk Capital
David Lapointe
Optina Diagnostics
Thierry Laugel
Kurma Partners

Taja Lester
Health Equity Capital
George Li
Proxima Ventures
Lisa Mendoza
Bayer
Andy Merken
Burns & Levinson

Junaid Mian
SP8CEVC
Neal Mody
Zoic Capital
Richard Morphy
Parkinson's UK
Richard Mulry
Northwell Ventures

Jonathan Ng
Iterative Scopes
Laurie Orlov
Aging and Health Technology
Martin Pfister
High-Tech Gründerfonds
Stephen Pitt
Johnson & Johnson Innovation

Varun Ramdevan
Johnson & Johnson Innovation
Meghana Rao
Johnson & Johnson Innovation
David Rhew
Microsoft
João Ribas
Novo Holdings A/S

Jeffrey Ries
Healthbox
Christopher Rowan
Cove Fund
Florence Rozen
Fonds de solidarité FTQ
Kerry Rupp
True Wealth Ventures

Chirag Shah
Define Ventures
Todd Smith
OdessaConnect
Sherri Snelling
Caregiving Club
Patrik Sobocki
Industrifonden

Catello Somma
TVM Capital Life Science
Weiyong Sun
Daiichi Sankyo
Hung-Loi (Lloyd) Tran
Transpacific Venture Capital Partners
Rick Voight
Vivid-Pi

Tad Weems
Agilent Technologies
Mishael Zohar
OrbiMed Advisors LLC
Khat Zorig
Innospark Ventures
Meghan Zubradt
Johnson & Johnson Innovation

Life Science Nation and YAFO Capital Announce ACCESS CHINA Forum (Spring 2021) – China Innovation Out-Licensing Event at Healthtech Partnering Week

25 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In 2021, Life Science Nation (LSN) launched the digital Healthtech Partnering Week (HPW), which consists of the renowned digital Redefining Early Stage Investments (RESI) 3-day event, 4D Meets AI 2-day event, and the Longevity, Health & Innovation (LHI) 2-day event, and now introducing ACCESS CHINA 2-day forum. LSN introduced this new open-concept conference theme in order that other independent conferences could participate in the week-long event with access to LSN’s premier partnering capability, which matches early-stage companies with strategic investment and licensing partners. HPW welcomes global partnering events to leverage the LSN global partner network, providing an incredible value to all attendees.

YAFO Capital‘s ACCESS CHINA Forum is a quarterly corporate access event series between China and Western biopharma. It is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global market. ACCESS CHINA Spring Forum, which focuses on China biotech innovation and out-licensing opportunities, adds to the HPW momentum. The Forum creates a great opportunity for LSN’s buy-side global partner network of investors, pharma and corporate strategics seeking equity and licensing opportunities to look at elite technology assets coming out of Asia. The scientist-entrepreneurs and fundraising CEOs coming to HPW via ACCESS CHINA Forum will be able to make new connections with global partners that will help them transition from their regional markets to the global arena.

LSN welcomes any firm that has a standalone life science partnering event happening simultaneously with HPW to join forces. YAFO Capital’s ACCESS CHINA Forum is a great example of how we can work together and deliver elite technology assets to a broader investor and strategic partner audience. Our goal is to reach across borders and events to raise the tide of early-stage partnering and lift all fundraising efforts in order to advance the latest in life-saving technologies and healthcare treatments.

Sign up to join Healthtech Partnering Week and take advantage of our global network of partners!

Free Webinar: Strategies for Successful Partnering

25 Feb

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN) has recently held two free webinars outlining strategies for successful partnering. Whether new to LSN and our early stage partnering events, or a frequent participant seeking to optimize their experience, it’s our goal that you have access to learn how to use the platform well, so you can spend more time meeting investors and making deals.

Healthtech Partnering Week (HPW) launches March 15-19, and there’s still time to sign up and even apply for the Innovator’s Pitch Challenge (IPC) – applications are due tomorrow, February 26! If you’re an early stage fundraising executive unsure of what makes a powerful partnering platform, we invite you to watch our latest webinar on strategies for success partnering. Learn more and sign up at https://www.healthtechpartneringweek.com/.

Hot Mandate: Investment Firm Focuses on Data-Driven Healthcare/Biotech Companies, with specific Interest In Big Data, AI, Computational Health & Digital Health

19 Feb

Founded 2013 and headquartered in San Francisco, the firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large-scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Boston Based VC Focuses on Pre-Seed to Seed Stage Companies Using Frontier Technologies, Such As Machine-learning, AI & Computational Biotech

19 Feb

A venture capital firm is founded in 2014 and headquartered in Boston, MA. The firm focuses on pre-seed and seed-stage investments, typically with an initial investment of $500K to $1M as part of the company’s first institutional funding. The firm prefers companies located in the US and Canada and is looking to make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though they’re comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: California Based VC With Accelerator Program Invests In Tech-Driven Companies, Including Digital Health Technologies with AI or Big Data Components

19 Feb

A venture capital firm based in California that invests in early-stage, technology-driven companies has recently started exploring life sciences/healthcare investment opportunities and is considering companies in various sectors. The initial check size of the firm can range from $500K – $2M. The firm also runs a program for those who has already participated in accelerator/incubator programs and want to further initial proofs of concept and early market validation to demonstrate long-term product/market fit, product roadmap, and business model. Companies that have already launched and want to expand go-to-market and reach profitability are welcome to participate in this program as well.

The firm invests in impactful, early-stage technology companies. Within life sciences and healthcare sectors, the firm is interested in medical devices (both 510k and PMA) with a strong data or hardware component and digital health technologies that leverage AI or big data analytics. The firm will not consider traditional therapeutics or diagnostics companies. In terms of disease area, the firm is opportunistic.

The firm can act as either lead or co-investor and is open to working with all kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

← Older Entries
Newer Entries →